| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S12282-012-0424-4 |
| P698 | PubMed publication ID | 23108629 |
| P2093 | author name string | Toshiro Niki | |
| Takashi Sakatani | |||
| Yasuo Hozumi | |||
| Yoshikazu Yasuda | |||
| Hideyuki Ohzawa | |||
| P2860 | cites work | Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer | Q27824847 |
| Trastuzumab in the adjuvant treatment of HER2-positive early breast cancer patients: a meta-analysis of published randomized controlled trials | Q33939795 | ||
| Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis | Q33969694 | ||
| Strategies for subtypes--dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011 | Q35130819 | ||
| Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patients | Q37898842 | ||
| Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases | Q42466825 | ||
| Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study | Q43121691 | ||
| Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall | Q43180234 | ||
| Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer | Q45287928 | ||
| Preoperative chemotherapy is safe in early breast cancer, even after 10 years of follow-up; clinical and translational results from the EORTC trial 10902. | Q46592618 | ||
| Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. | Q46765380 | ||
| Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy | Q46856598 | ||
| Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. | Q52893849 | ||
| 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. | Q53243856 | ||
| The efficacy of HER2-targeted agents in metastatic breast cancer: a meta-analysis. | Q54629593 | ||
| A simple system for grading the response of breast cancer to neoadjuvant chemotherapy. | Q54723633 | ||
| P433 | issue | 5 | |
| P304 | page(s) | 563-570 | |
| P577 | publication date | 2012-10-30 | |
| P1433 | published in | Breast Cancer | Q15752871 |
| P1476 | title | Pathological responses and survival of patients with human epidermal growth factor receptor 2-positive breast cancer who received neoadjuvant chemotherapy including trastuzumab | |
| P478 | volume | 21 |
| Q36977429 | Breast cancer molecular subtypes and survival in a hospital-based sample in Puerto Rico |
| Q34427448 | Effect of PREDICT on chemotherapy/trastuzumab recommendations in HER2-positive patients with early-stage breast cancer |
| Q46542099 | Neoadjuvant chemotherapy for different molecular breast cancer subtypes: a retrospective study in Russian population. |
| Q36838312 | Ten-Year Outcomes of Patients With Breast Cancer With Cytologically Confirmed Axillary Lymph Node Metastases and Pathologic Complete Response After Primary Systemic Chemotherapy |
Search more.